Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)Rajat Bannerji, Max S. Topp, John N. Allan et al.|Blood|2019Cited by 57
Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2Won-Seog Kim, Jan Walewski, Francesca Lim et al.|Blood|2022Cited by 28
Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed Antibody TherapyRajat Bannerji, Carrie Brownstein, Jennifer R. Brown et al.|Blood|2016Cited by 19
P1115: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2Jan Walewski, Won-Seog Kim, Tae Min Kim et al.|HemaSphere|2023Cited by 5